{"nct_id":"NCT06570798","title":"A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-07-16","start_date_type":"ACTUAL","primary_completion_date":"2028-09-15","primary_completion_date_type":"ESTIMATED","completion_date":"2029-06-23","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["AMGN"]}